1. Home
  2. RNTX vs PLUT Comparison

RNTX vs PLUT Comparison

Compare RNTX & PLUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • PLUT
  • Stock Information
  • Founded
  • RNTX 2001
  • PLUT 2018
  • Country
  • RNTX United States
  • PLUT Hong Kong
  • Employees
  • RNTX N/A
  • PLUT N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • PLUT
  • Sector
  • RNTX Health Care
  • PLUT
  • Exchange
  • RNTX Nasdaq
  • PLUT NYSE
  • Market Cap
  • RNTX 40.3M
  • PLUT 35.6M
  • IPO Year
  • RNTX N/A
  • PLUT 2025
  • Fundamental
  • Price
  • RNTX $1.56
  • PLUT $2.25
  • Analyst Decision
  • RNTX
  • PLUT
  • Analyst Count
  • RNTX 0
  • PLUT 0
  • Target Price
  • RNTX N/A
  • PLUT N/A
  • AVG Volume (30 Days)
  • RNTX 33.6K
  • PLUT 29.5K
  • Earning Date
  • RNTX 08-13-2025
  • PLUT 01-01-0001
  • Dividend Yield
  • RNTX N/A
  • PLUT N/A
  • EPS Growth
  • RNTX N/A
  • PLUT N/A
  • EPS
  • RNTX N/A
  • PLUT N/A
  • Revenue
  • RNTX N/A
  • PLUT $1,435,597.00
  • Revenue This Year
  • RNTX N/A
  • PLUT N/A
  • Revenue Next Year
  • RNTX N/A
  • PLUT N/A
  • P/E Ratio
  • RNTX N/A
  • PLUT N/A
  • Revenue Growth
  • RNTX N/A
  • PLUT 1.42
  • 52 Week Low
  • RNTX $1.35
  • PLUT $2.07
  • 52 Week High
  • RNTX $4.40
  • PLUT $4.22
  • Technical
  • Relative Strength Index (RSI)
  • RNTX N/A
  • PLUT N/A
  • Support Level
  • RNTX N/A
  • PLUT N/A
  • Resistance Level
  • RNTX N/A
  • PLUT N/A
  • Average True Range (ATR)
  • RNTX 0.00
  • PLUT 0.00
  • MACD
  • RNTX 0.00
  • PLUT 0.00
  • Stochastic Oscillator
  • RNTX 0.00
  • PLUT 0.00

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About PLUT PLUTUS FINANCIAL GROUP LIMITED

Plutus Financial Group Ltd provides financial services. It mainly offers (i) securities dealings and brokerage services (ii) margin financing services and (iii) underwriting and placing services.

Share on Social Networks: